(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Global Fund aims for the first shipment to reach at least one African country by year-end. Read more at straitstimes.com.

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

U.S. withdrawal of $4 billion in AIDS funding risks over 4 million deaths and 6 million new HIV infections by 2029 ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...